Enzon Pharmaceuticals EBIT

Enzon Pharmaceuticals (ENZN) currently reports a EBIT of $-6.3M as of June 2026. That compares with $-430K in the prior-year period — down 1341.2% year over year. That is below the Healthcare sector average of $23B. Use the charts on this page to explore Enzon Pharmaceuticals's EBIT history and peer comparisons.

Enzon Pharmaceuticals's EBIT decreased from $-430K to $-6.3M — a 1341.2% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Enzon Pharmaceuticals's EBIT of $-6.3M is lower than the Healthcare sector average of $23B. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Enzon Pharmaceuticals reported $-6.3M in EBIT as of June 2026. That compares with $-430K in the prior-year period — down 1341.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-6.3M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $23B. From there, open related valuation or income-statement pages for Enzon Pharmaceuticals, and consider following ENZN for alerts when major investors trade the stock.